4.7 Article

P-glycoprotein antibody-conjugated paclitaxel liposomes targeted for multidrug-resistant lung cancer

期刊

NANOMEDICINE
卷 18, 期 10, 页码 819-831

出版社

FUTURE MEDICINE LTD
DOI: 10.2217/nnm-2023-0015

关键词

liposomes; lung cancer; multidrug resistance; P-glycoprotein antibody conjugated; paclitaxel

向作者/读者索取更多资源

This study aimed to overcome the resistance of lung cancer cells to paclitaxel by preparing P-glycoprotein antibody-conjugated paclitaxel PEG-coated immunoliposomes (Pab-PTX-L). The results showed that Pab-PTX-L had nano-sized particles with high encapsulation efficiency of paclitaxel and exhibited better cellular uptake, cell viability inhibition, and apoptosis induction in paclitaxel-resistant lung cancer cells. Moreover, Pab-PTX-L demonstrated good tumor-targeting and antitumor effects in mouse experiments.
Aims: To overcome the resistance of lung cancer to paclitaxel. Methods: P-glycoprotein antibody-conjugated paclitaxel PEG-coated immunoliposomes (Pab-PTX-L) were prepared, and a series of quality evaluations, in vitro cell evaluation and assessment of their in vivo antitumor effect in mice were conducted. Results: The results showed that Pab-PTX-L was nano-sized with high encapsulation efficiency of paclitaxel. For the paclitaxel-resistant lung cancer A549/T cells, the cellular uptake and cell viability inhibition and apoptosis of Pab-PTX-L-treated cells were higher than those of the control groups. More importantly, Pab-PTX-L showed a good targeting and antitumor effect on tumor tissue in mouse experiments. Conclusion: This study will provide a new insight on enhanced paclitaxel delivery into paclitaxel-resistant cancer cells.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据